



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Rd,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### Nasovac-S - WHO PreQualification certification received

Melbourne, 21 October 2015:

BioDiem Ltd is pleased to announce that Serum Institute of India (SII), one of BioDiem's LAIV technology commercial licencees, has received WHO prequalification (PQ) certification for their LAIV vaccine product, Nasovac-S™.

Nasovac-S is SII's seasonal influenza vaccine which was launched into the Indian market in July 2014. The WHO PQ will open the market for Nasovac-S in the PAHO region and other UNICEF countries. SII will also be able to export to other markets however some regulatory review may be required in other export countries. This certification has been eagerly awaited and according to SII, relevant tenders should be open during 2016. One of SII's strengths is in targeting tenders in developing countries.

For further information please contact:

**Julie Phillips**  
Chief Executive Officer  
Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)  
Ph +61 9692 7240  
Twitter @biodiem

- ENDS -

## About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit [www.biodiem.com](http://www.biodiem.com).

### **About Serum Institute of India**

Serum Institute of India Ltd. is now the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 140 countries across the globe in their national immunization programs, saving millions of lives throughout the world.

Serum Institute of India is ranked as India's No. 1 biotechnology company, manufacturing highly specialized life saving biologicals like vaccines using cutting edge genetic and cell based technologies, antisera and other medical specialties. For further information, please visit [www.seruminstitute.com](http://www.seruminstitute.com)